Guangliang Qiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guangliang Qiang has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
Chutong Lin
Department of thoracic surgery, Peking University Third Hospital
11 shared publicationsYingze Ning
Department of Thoracic Surgery Peking University Third Hospital Beijing China
10 shared publicationsFangjun Chen
7 shared publicationsShanwu Ma
Thoracic Surgery Department, Peking University Third Hospital, Beijing, China
7 shared publicationsJizheng Tang
Department of thoracic surgery, Peking University Third Hospital
6 shared publicationsRui Xu
5 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Wiley in IUBMB Life
- Vol. 78 (11)
ACOT11 Couples Lipid Hydrolysis to GPR40‐Associated Metabolic Rewiring and Neutrophil–PD‐L1‐Associated Immunomodulation in Non‐Small Cell Lung Cancer
Chemoresistance in non‐small cell lung cancer (NSCLC) is frequently accompanied by metabolic reprogramming and immune evasion. ACOT11 (THEM1/STARD14) is an acyl‐CoA thioesterase that can tune intracellular free fatty acid (FFA) availability, but the downstream signaling and microenvironmental consequences relevant to resistance remain incompletely defined. ACOT11 expression and prognostic associations were analyzed in TCGA LUAD datasets (DESeq2) and Kaplan–Meier Plotter. ACOT11 levels were validated in paired patient tumor/adjacent tissues ( n = 30) by RT–qPCR and immunohistochemistry. Gain‐ and loss‐of‐function studies were performed in A549 and NCI‐H1975 cells. FFAs were quantified colorimetrically/fluorometrically, while proliferation, clonogenicity, and motility were assessed using CCK‐8, colony formation, and Transwell assays. Bioenergetic profiling was performed by Seahorse OCR/ECAR measurements, complemented by ATP and lactate quantification. Neutrophils and CD8 + T cells were isolated from PBMCs for co‐culture assays with PD‐L1 blockade, and PD‐L1 was quantified by flow cytometry and immunoblotting. Tumor growth effects were evaluated in nude mouse xenografts with ACOT11 silencing and neutrophil supplementation. ACOT11 was dysregulated in LUAD and associated with worse survival, and was elevated in clinical tumors at mRNA and protein levels. In NSCLC cells, ACOT11 increased FFA abundance and selectively changes in GPR40 but not GPR120. Exogenous FFA partially rescued the proliferative and migratory defects induced by ACOT11 knockdown, and this rescue was blunted by GPR40 co‐silencing. ACOT11 depletion reduced OCR/ECAR, ATP, and lactate output, consistent with impaired energetic capacity, whereas FFA restored these parameters in a GPR40‐dependent manner, suggesting that this pathway likely contributes to the observed metabolic effects. ACOT11 aligned with neutrophil‐associated inflammatory signatures and increased MPO staining in tumors; ACOT11 loss reduced SPP1/CXCL2 expression, reversible by FFA–GPR40 signaling. Functionally, neutrophils were observed to restore PD‐L1 levels and suppress T‐cell effector outputs in co‐culture settings, and neutrophil supplementation partially rescued xenograft growth; PD‐L1 blockade enhanced T‐cell cytokine/perforin production and migration. Collectively, these findings support a working model in which ACOT11‐associated lipid signaling may contribute to an immunosuppressive milieu involving neutrophils and PD‐L1. ACOT11 is associated with increased FFA availability and engagement of a GPR40‐linked metabolic program, alongside neutrophil–PD‐L1‐associated immunosuppression, which may collectively contribute to NSCLC fitness. Targeting components of the ACOT11‐FFA‐GPR40 pathway, alone or combined with PD‐L1 blockade, may represent a mechanistically grounded strategy to weaken tumor bioenergetic reserve and immune escape in NSCLC.
- 13 November 2026
- Published by Wiley in IUBMB Life
- Vol. 78 (11)
Open AccessACOT11 Couples Lipid Hydrolysis to GPR40‐Associated Metabolic Rewiring and Neutrophil–PD‐L1‐Associated Immunomodulation in Non‐Small Cell Lung Cancer
Chemoresistance in non‐small cell lung cancer (NSCLC) is frequently accompanied by metabolic reprogramming and immune evasion. ACOT11 (THEM1/STARD14) is an acyl‐CoA thioesterase that can tune intracellular free fatty acid (FFA) availability, but the downstream signaling and microenvironmental consequences relevant to resistance remain incompletely defined. ACOT11 expression and prognostic associations were analyzed in TCGA LUAD datasets (DESeq2) and Kaplan–Meier Plotter. ACOT11 levels were validated in paired patient tumor/adjacent tissues ( n = 30) by RT–qPCR and immunohistochemistry. Gain‐ and loss‐of‐function studies were performed in A549 and NCI‐H1975 cells. FFAs were quantified colorimetrically/fluorometrically, while proliferation, clonogenicity, and motility were assessed using CCK‐8, colony formation, and Transwell assays. Bioenergetic profiling was performed by Seahorse OCR/ECAR measurements, complemented by ATP and lactate quantification. Neutrophils and CD8 + T cells were isolated from PBMCs for co‐culture assays with PD‐L1 blockade, and PD‐L1 was quantified by flow cytometry and immunoblotting. Tumor growth effects were evaluated in nude mouse xenografts with ACOT11 silencing and neutrophil supplementation. ACOT11 was dysregulated in LUAD and associated with worse survival, and was elevated in clinical tumors at mRNA and protein levels. In NSCLC cells, ACOT11 increased FFA abundance and selectively changes in GPR40 but not GPR120. Exogenous FFA partially rescued the proliferative and migratory defects induced by ACOT11 knockdown, and this rescue was blunted by GPR40 co‐silencing. ACOT11 depletion reduced OCR/ECAR, ATP, and lactate output, consistent with impaired energetic capacity, whereas FFA restored these parameters in a GPR40‐dependent manner, suggesting that this pathway likely contributes to the observed metabolic effects. ACOT11 aligned with neutrophil‐associated inflammatory signatures and increased MPO staining in tumors; ACOT11 loss reduced SPP1/CXCL2 expression, reversible by FFA–GPR40 signaling. Functionally, neutrophils were observed to restore PD‐L1 levels and suppress T‐cell effector outputs in co‐culture settings, and neutrophil supplementation partially rescued xenograft growth; PD‐L1 blockade enhanced T‐cell cytokine/perforin production and migration. Collectively, these findings support a working model in which ACOT11‐associated lipid signaling may contribute to an immunosuppressive milieu involving neutrophils and PD‐L1. ACOT11 is associated with increased FFA availability and engagement of a GPR40‐linked metabolic program, alongside neutrophil–PD‐L1‐associated immunosuppression, which may collectively contribute to NSCLC fitness. Targeting components of the ACOT11‐FFA‐GPR40 pathway, alone or combined with PD‐L1 blockade, may represent a mechanistically grounded strategy to weaken tumor bioenergetic reserve and immune escape in NSCLC.
- Open Access
- 9 November 2026
- Published by Springer Nature in BMC Medical Imaging
Incremental prognostic value of CT radiomics and deep learning beyond complete tumor volume in non-small cell lung cancer: a reanalysis of LUNG1
- 9 November 2026
- Published by Springer Nature in BMC Medical Imaging
Open AccessIncremental prognostic value of CT radiomics and deep learning beyond complete tumor volume in non-small cell lung cancer: a reanalysis of LUNG1
- Open Access
- 3 November 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1852087
Neurotoxicity associated with ALK inhibitors in the treatment of non-small cell lung cancer: an analysis of the FAERS database
Background: ALK inhibitors (ALKis) have substantially improved outcomes in ALK-positive non-small cell lung cancer (NSCLC). Neurological adverse events (AEs) remain clinically relevant, but their reporting patterns and reported time-to-onset (TTO) characteristics in routine pharmacovigilance require further characterization. Methods: Neurological AE reports recorded with five ALK inhibitors (crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib) were extracted from FAERS (Q1 2004–Q1 2025). Reporting disproportionality was evaluated at the preferred-term (PT) level using the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN). TTO analyses were restricted to reports with evaluable timing information, and exploratory subgroup analyses characterized reporting-signal patterns by age, sex, and reporter type. Results: The final analysis included 1,473 report-level reports and 2,274 PT-level neurological AE records; one report could contain more than one PT. Lorlatinib, ceritinib, brigatinib, crizotinib, and alectinib had 29, 15, 12, 9, and 9 PTs, respectively, that met all three disproportionality criteria. Among the 1,473 reports, 577 (39.17%) had evaluable TTO information. Recorded onset times among these evaluable reports were more concentrated in the earlier period after treatment initiation, but this distribution does not estimate incidence, absolute risk, or hazard among all exposed patients. Conclusion: This pharmacovigilance analysis identifies drug-specific patterns of reported neurological AEs and reported TTO among ALK inhibitors. The findings support clinical awareness and hypothesis generation, but they do not establish causality or comparative clinical safety and should be evaluated in studies with exposure denominators and control of confounding.
- 3 November 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1852087
Open AccessNeurotoxicity associated with ALK inhibitors in the treatment of non-small cell lung cancer: an analysis of the FAERS database
Background: ALK inhibitors (ALKis) have substantially improved outcomes in ALK-positive non-small cell lung cancer (NSCLC). Neurological adverse events (AEs) remain clinically relevant, but their reporting patterns and reported time-to-onset (TTO) characteristics in routine pharmacovigilance require further characterization. Methods: Neurological AE reports recorded with five ALK inhibitors (crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib) were extracted from FAERS (Q1 2004–Q1 2025). Reporting disproportionality was evaluated at the preferred-term (PT) level using the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN). TTO analyses were restricted to reports with evaluable timing information, and exploratory subgroup analyses characterized reporting-signal patterns by age, sex, and reporter type. Results: The final analysis included 1,473 report-level reports and 2,274 PT-level neurological AE records; one report could contain more than one PT. Lorlatinib, ceritinib, brigatinib, crizotinib, and alectinib had 29, 15, 12, 9, and 9 PTs, respectively, that met all three disproportionality criteria. Among the 1,473 reports, 577 (39.17%) had evaluable TTO information. Recorded onset times among these evaluable reports were more concentrated in the earlier period after treatment initiation, but this distribution does not estimate incidence, absolute risk, or hazard among all exposed patients. Conclusion: This pharmacovigilance analysis identifies drug-specific patterns of reported neurological AEs and reported TTO among ALK inhibitors. The findings support clinical awareness and hypothesis generation, but they do not establish causality or comparative clinical safety and should be evaluated in studies with exposure denominators and control of confounding.
- Open Access
- 1 September 2026
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 16 (9) , 755
Air embolism occurred during preoperative localization for pulmonary resection: a case description
Air embolism occurred during preoperative localization for pulmonary resection: a case description
- 1 September 2026
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 16 (9) , 755
Open AccessAir embolism occurred during preoperative localization for pulmonary resection: a case description
Air embolism occurred during preoperative localization for pulmonary resection: a case description
- Open Access
- 19 August 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
SWIR-responsive SeTe nanoparticles integrate antibacterial activity and selenoprotein-associated redox regulation for infected bone defect repair
- 19 August 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessSWIR-responsive SeTe nanoparticles integrate antibacterial activity and selenoprotein-associated redox regulation for infected bone defect repair
- 10 July 2026
- Published by Elsevier in Tissue and Cell
- Vol. 104 (Pt 1) , 103764
LINC02126 stabilized by YTHDC1-mediated m6A modification suppresses lung adenocarcinoma progression by sponging miR-501-5p
- 10 July 2026
- Published by Elsevier in Tissue and Cell
- Vol. 104 (Pt 1) , 103764
LINC02126 stabilized by YTHDC1-mediated m6A modification suppresses lung adenocarcinoma progression by sponging miR-501-5p
- Open Access
- 3 July 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Multi-center validated attention-BiFPN deep learning for CT-based lung cancer subtype classification
- 3 July 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Open AccessMulti-center validated attention-BiFPN deep learning for CT-based lung cancer subtype classification
- Open Access
- 1 July 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (7) , 767
Machine learning models based on XGBoost algorithm to predict prognosis of lung cancer brain metastases
Background: Lung cancer is the leading cause of cancer-related death worldwide, and brain metastasis (LCBM) is among its most lethal complications with limited prognostic tools. This study aimed to build a machine learning model using the extreme gradient boosting (XGBoost) algorithm to predict the prognosis of lung cancer brain metastasis (LCBM) patients more accurately. Methods: Data from 15,216 patients with synchronous LCBM in the Surveillance, Epidemiology, and End Results (SEER) database diagnosed between 2010 and 2014 were used for model development and internal testing, while a temporally distinct cohort of 3,181 patients diagnosed in 2015 was used for temporal validation. The XGBoost algorithm was trained to predict 6-month, 1-, 2-, and 3-year overall survival, incorporating 13 clinical variables identified via multivariate Cox regression. Model performance was comprehensively evaluated via area under the curve (AUC) of the receiver operating characteristic (ROC) curve, confusion matrix, calibration curves, and decision curve analysis. Pairwise AUC comparisons between models were performed using the DeLong test with Holm correction for multiple comparisons. Propensity score matching (PSM) and Kaplan-Meier analysis were conducted to explore the association between surgical treatment and survival. Results: The XGBoost model achieved AUC values ranging from 0.805 to 0.822 and 0.796 to 0.816 in the training and test sets, respectively, and 0.780 to 0.822 in temporal validation. DeLong test confirmed statistically significant differences in AUC between XGBoost and all four competing models across all follow-up time points (all adjusted PConclusions: The XGBoost model demonstrated good discriminative performance, excellent calibration, and superior clinical net benefit for survival prediction in synchronous LCBM patients using routine clinical variables. Chemotherapy showed the highest predictive importance, though treatment-related variables are subject to confounding by indication. Exploratory analyses suggest heterogeneous associations between surgery and survival across clinical subgroups, warranting prospective validation. These findings provide robust evidence supporting the clinical utility of the XGBoost model as a promising prognostic tool for LCBM patients.
- 1 July 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (7) , 767
Open AccessMachine learning models based on XGBoost algorithm to predict prognosis of lung cancer brain metastases
Background: Lung cancer is the leading cause of cancer-related death worldwide, and brain metastasis (LCBM) is among its most lethal complications with limited prognostic tools. This study aimed to build a machine learning model using the extreme gradient boosting (XGBoost) algorithm to predict the prognosis of lung cancer brain metastasis (LCBM) patients more accurately. Methods: Data from 15,216 patients with synchronous LCBM in the Surveillance, Epidemiology, and End Results (SEER) database diagnosed between 2010 and 2014 were used for model development and internal testing, while a temporally distinct cohort of 3,181 patients diagnosed in 2015 was used for temporal validation. The XGBoost algorithm was trained to predict 6-month, 1-, 2-, and 3-year overall survival, incorporating 13 clinical variables identified via multivariate Cox regression. Model performance was comprehensively evaluated via area under the curve (AUC) of the receiver operating characteristic (ROC) curve, confusion matrix, calibration curves, and decision curve analysis. Pairwise AUC comparisons between models were performed using the DeLong test with Holm correction for multiple comparisons. Propensity score matching (PSM) and Kaplan-Meier analysis were conducted to explore the association between surgical treatment and survival. Results: The XGBoost model achieved AUC values ranging from 0.805 to 0.822 and 0.796 to 0.816 in the training and test sets, respectively, and 0.780 to 0.822 in temporal validation. DeLong test confirmed statistically significant differences in AUC between XGBoost and all four competing models across all follow-up time points (all adjusted PConclusions: The XGBoost model demonstrated good discriminative performance, excellent calibration, and superior clinical net benefit for survival prediction in synchronous LCBM patients using routine clinical variables. Chemotherapy showed the highest predictive importance, though treatment-related variables are subject to confounding by indication. Exploratory analyses suggest heterogeneous associations between surgery and survival across clinical subgroups, warranting prospective validation. These findings provide robust evidence supporting the clinical utility of the XGBoost model as a promising prognostic tool for LCBM patients.
- Open Access
- 10 June 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (11) , e70320
Synchronous Surgical Therapy for Bilateral Multiple Pulmonary Nodules: A Single‐Center Analysis of 108 Cases
Background: With the widespread use of low‐dose computed tomography (LDCT), the detection rate of bilateral multiple pulmonary nodules (BMPNs) has increased significantly. Surgical treatment remains the main treatment for multiple pulmonary nodules (MPNs), and its therapeutic value for simultaneous BMPNs is becoming increasingly prominent. However, the safety and feasibility of synchronous bilateral surgery (SBS) remain underexplored. This study aimed to evaluate the perioperative outcomes and prognosis of patients who underwent SBS for multiple pulmonary nodules. Methods: We retrospectively analyzed the data from 108 patients who underwent synchronous bilateral resection for MPNs at Peking University Third Hospital between January 2015 and December 2025. Clinical, pathological, and perioperative data were collected. Postoperative complications were classified using the Clavien–Dindo system. Risk factors for postoperative complications were identified using a logistic regression analysis. Overall survival was estimated using the Kaplan–Meier method. Results: Among the 108 patients, 62.0% were female, and 79.6% were nonsmokers. The most common surgical combination was wedge resection combined with wedge resection (44.4%). The mean postoperative hospital stay was 6.55 ± 3.03 days. The most common complications were constipation (53.7%) and sleep disorders (51.9%), while severe complications occurred in fewer than 5% of the patients. No 30‐day mortality or unplanned secondary surgery was observed. Prolonged chest tube drainage (> 3 days) was identified as an independent risk factor for grade ≥ 2 complications ( p < 0.05). The 5‐year overall survival rate was 92.3%. Conclusions: SBS for MPNs is safe and feasible in selected patients, with acceptable perioperative outcomes and favorable survival.
- 10 June 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (11) , e70320
Open AccessSynchronous Surgical Therapy for Bilateral Multiple Pulmonary Nodules: A Single‐Center Analysis of 108 Cases
Background: With the widespread use of low‐dose computed tomography (LDCT), the detection rate of bilateral multiple pulmonary nodules (BMPNs) has increased significantly. Surgical treatment remains the main treatment for multiple pulmonary nodules (MPNs), and its therapeutic value for simultaneous BMPNs is becoming increasingly prominent. However, the safety and feasibility of synchronous bilateral surgery (SBS) remain underexplored. This study aimed to evaluate the perioperative outcomes and prognosis of patients who underwent SBS for multiple pulmonary nodules. Methods: We retrospectively analyzed the data from 108 patients who underwent synchronous bilateral resection for MPNs at Peking University Third Hospital between January 2015 and December 2025. Clinical, pathological, and perioperative data were collected. Postoperative complications were classified using the Clavien–Dindo system. Risk factors for postoperative complications were identified using a logistic regression analysis. Overall survival was estimated using the Kaplan–Meier method. Results: Among the 108 patients, 62.0% were female, and 79.6% were nonsmokers. The most common surgical combination was wedge resection combined with wedge resection (44.4%). The mean postoperative hospital stay was 6.55 ± 3.03 days. The most common complications were constipation (53.7%) and sleep disorders (51.9%), while severe complications occurred in fewer than 5% of the patients. No 30‐day mortality or unplanned secondary surgery was observed. Prolonged chest tube drainage (> 3 days) was identified as an independent risk factor for grade ≥ 2 complications ( p < 0.05). The 5‐year overall survival rate was 92.3%. Conclusions: SBS for MPNs is safe and feasible in selected patients, with acceptable perioperative outcomes and favorable survival.
- Open Access
- 30 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 4963
CCR5+ CD8+ T Cells Are Associated with Poor Response to PD-1 Blockade Therapy
Many patients develop poor clinical response to immune checkpoint inhibitors (ICIs), especially PD-1/PD-L1 blockade. However, transcriptomic features of chemokine receptors associated with poor response remain incompletely characterized. We analyzed publicly available single-cell RNA sequencing datasets from non-small-cell lung cancer (NSCLC) and melanoma cohorts, with additional exploratory analyses in hepatocellular carcinoma (HCC) and colorectal cancer datasets. Chemokine receptor expression on CD8+ T cells from clinical responsive and non-responsive samples to anti-PD-1 therapy was systematically profiled. Differential gene expression, cell-state scoring, pseudotime trajectory inference, and ligand–receptor interaction analysis were performed to characterize associated transcriptional states and predicted cellular interactions. CCR5 transcript expression in tumor-infiltrating CD8+ T cells was associated with lower responsiveness to PD-1/PD-L1 blockade therapy. CCR5+ CD8+ T cells exhibited transcriptional features associated with increased exhaustion, reduced stemness, and advanced differentiation. Pseudotime inference suggested progressively increased CCR5 expression along the inferred differentiation trajectory. Ligand–receptor interaction analysis further identified predicted interactions between CCR5+ CD8+ T cells and tumor-associated myeloid cells, with elevated expression of CCL3 and CCL4 observed in myeloid populations from non-responsive tumors. Together, these findings identify transcriptomic associations between CCR5+ CD8+ T cell states and poor clinical response to PD-1 blockade therapy. These observations support the CCL3/4–CCR5 axis as a candidate pathway for future spatial, functional, and experimental validation.
- 30 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 4963
Open AccessCCR5+ CD8+ T Cells Are Associated with Poor Response to PD-1 Blockade Therapy
Many patients develop poor clinical response to immune checkpoint inhibitors (ICIs), especially PD-1/PD-L1 blockade. However, transcriptomic features of chemokine receptors associated with poor response remain incompletely characterized. We analyzed publicly available single-cell RNA sequencing datasets from non-small-cell lung cancer (NSCLC) and melanoma cohorts, with additional exploratory analyses in hepatocellular carcinoma (HCC) and colorectal cancer datasets. Chemokine receptor expression on CD8+ T cells from clinical responsive and non-responsive samples to anti-PD-1 therapy was systematically profiled. Differential gene expression, cell-state scoring, pseudotime trajectory inference, and ligand–receptor interaction analysis were performed to characterize associated transcriptional states and predicted cellular interactions. CCR5 transcript expression in tumor-infiltrating CD8+ T cells was associated with lower responsiveness to PD-1/PD-L1 blockade therapy. CCR5+ CD8+ T cells exhibited transcriptional features associated with increased exhaustion, reduced stemness, and advanced differentiation. Pseudotime inference suggested progressively increased CCR5 expression along the inferred differentiation trajectory. Ligand–receptor interaction analysis further identified predicted interactions between CCR5+ CD8+ T cells and tumor-associated myeloid cells, with elevated expression of CCL3 and CCL4 observed in myeloid populations from non-responsive tumors. Together, these findings identify transcriptomic associations between CCR5+ CD8+ T cell states and poor clinical response to PD-1 blockade therapy. These observations support the CCL3/4–CCR5 axis as a candidate pathway for future spatial, functional, and experimental validation.